Abstracts tagged "race/ethnicity"

Abstract Number: 0956 • ACR Convergence 2021
Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition
Joyce Chang¹, Cora Sears², Veronica Torres³ and Mary Beth Son¹, ¹Boston Children's Hospital, Brookline, MA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Temple University, Bucks County, PA
Background/Purpose: Racial and ethnic minorities are disproportionately affected by pediatric-onset SLE and have worse outcomes compared to their white counterparts. With ongoing advances in pediatric…
Abstract Number: 1023 • ACR Convergence 2021
Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network
William Nowell¹, Edward L. Barnes², Nupur Parikh¹, Shilpa Venkatachalam¹, Michael Kappelman², Jeffrey Curtis³, Peter Merkel⁴, Dianne Shaw⁵, Kalen Young⁵ and Michael George⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO
Background/Purpose: Ensuring adequate representation of racial/ethnic minorities in research necessitates understanding the prevalence of rheumatic and musculoskeletal diseases in these populations. We sought to evaluate…
Abstract Number: 0326 • ACR Convergence 2021
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Michelle Petri¹, Romy Kallas², Jessica Li³, Laurence Magder⁴ and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lankenau Medical Center, Lankenau, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide…
Abstract Number: 1034 • ACR Convergence 2021
Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study
Bella Mehta¹, Yiming Luo², Deanna Jannat-Khah³, Jiehui Xu⁴, Lisa Sammaritano³, Jane Salmon³, Michael Lockshin¹, Susan Goodman³ and Said Ibrahim⁵, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²National Institutes of Health, Bethesda, MD, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵Weill Cornell Medicine, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects women and minorities of childbearing age. Although maternal and fetal outcomes of pregnancy among women with SLE have…
Abstract Number: 0339 • ACR Convergence 2021
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
Anum Akhlaq¹ and Abdul Mannan Khan Minhas², ¹Orange Park Medical Center, Orange Park, FL, ²Forrest General Hospital, Hattiesburg
Background/Purpose: Important disparities in SLE patients persist based on their sex and racial/ethnic status. The aim of this study is to examine the trends in…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 0349 • ACR Convergence 2021
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
Jessica English¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
Abstract Number: 1589 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy in Rheumatology Patients
Rebecca Sadun¹, Amanda Eudy¹, Jennifer Rogers¹, Kai Sun², Lisa Criscione-Schreiber², Mithu Maheswaranathan², Jayanth Doss¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for…
Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Mia Chandler¹, Leah Santacroce², Karen Costenbader³, Rishi Desai⁴, Seoyoung Kim² and Candace Feldman², ¹Boston Children's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Belmont, MA, ⁴Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…
Abstract Number: 1611 • ACR Convergence 2021
A Population-Based Evaluation of Telemedicine Use and Satisfaction in SLE Patients During the COVID-19 Pandemic in Atlanta, Georgia
Sarah Simmons¹, Cristina Drenkard², Gaobin Bao², Charmayne Dunlop-Thomas², Kim Schofield² and S Sam Lim³, ¹Duke University, Durham, NC, ²Emory University, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic resulted in the shift from in-person physician appointments to the development and proliferation of the use of telemedicine in an attempt…
Abstract Number: 0594 • ACR Convergence 2021
The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
Titilola Falasinnu¹, Nada Rizk¹, Becca Feldman², Devy Zisman³, Michael Leshchinsky², Gabriella Lawrence², Yashaar Chaichian⁴ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Stanford University, Los Gatos, CA
Background/Purpose: Misclassification of race and ethnicity in data can impact how disparities in prevalence, incidence, severity, and complications of systemic lupus erythematosus (SLE) are interpreted.…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 0596 • ACR Convergence 2021
Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs
Shannon Grabich¹, Cullen Seal², Robert Ortmann³ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: SLE is a chronic, multisystem autoimmune disease characterized by reoccurring flares and remissions. It is more common among Asian, Black, and Hispanic populations. Racial…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].